s
s
s
Develop highly selective and sensitive PK and ADA assays for the humanized antibody drug ramucirumab (Cyramza) using our range of ready-made anti-idiotypic antibodies.
Table 1. Antibodies specific to ramucirumab
Specificity Binding Type |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Ramucirumab Inhibitory Type 1 |
HCA407 |
AbD51672ia |
hIgG1 |
<0.1 |
ADA Control |
|
HCA408 |
AbD53006ia |
hIgG1 |
0.8 |
ADA Control |
||
HCA409 |
AbD53014ia |
hIgG1 |
1.4 |
ADA Control |
||
TZA050 |
AbD51673ad |
Fab-F-Spy2-H1 |
0.3 |
PK bridging ELISA (capture) |
||
TZA051 |
AbD51668ad |
Fab-F-Spy2-H1 |
1 |
PK bridging ELISA (detection) |
||
TZA051P |
AbD51668pap |
Fab2-FH-X22-HRP2 |
1 |
PK bridging ELISA (detection) |
||
Ramucirumab & Ramucirumab / VEGFR2 Non Inhibitory Type 2 |
TZA052 |
AbD53018ad |
Fab-F-Spy2-H1 |
17 |
PK bridging ELISA (detection) |
|
TZA052P |
AbD53018pap |
Fab2-FH-X22-HRP2 |
17 |
PK bridging ELISA (detection) |
||
Ramucirumab / VEGFR2 Complex Specific Type 3 |
TZA053 |
AbD53034ad |
Fab-F-Spy2-H1 |
1 |
PK antigen capture ELISA |
|
TZA053P |
AbD53034pap |
Fab2-FH-X22-HRP2 |
1 |
PK antigen capture ELISA |
* Affinity measured in the monovalent Fab format.
1 Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2 and (H) His6 tags.
2 Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags and Fab-SpyTag coupled to HRP conjugated BiCatcher
The Type 1 anti-ramucirumab antibodies inhibit the binding of the drug ramucirumab to its target, the vascular endothelial growth factor receptor 2 (VEGFR2). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format, they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
The type 2 anti-ramucirumab antibody binds to the ramucirumab idiotope but does not inhibit the binding of ramucirumab to VEGFR2. It can therefore be used in combination with a type 1 antibody in a PK bridging ELISA to measure free and partially bound drug.
The Type 3 antibody specifically recognizes the drug-target complex, detecting ramucirumab only when it is bound to VEGFR2. It is suitable as a detection antibody in a PK antigen capture assay.
Fig. 1. Ramucirumab PK bridging ELISA using antibodies TZA050 and TZA051P.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.
Fig. 2. Ramucirumab PK bridging ELISA using antibodies TZA050 and TZA052P
Schematic image of PK bridging ELISA measuring free and partially bound drug. Type 1 anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), drug target (red), type 2 anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
Fig. 3. Ramucirumab PK antigen capture ELISA using antibody TZA053P.
Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug target complex detection antibody, monovalent Fab format (purple), labeled with HRP.
Fig. 4. Ramucirumab ADA bridging ELISA using antibody HCA407, HCA408 and HCA409.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.